CANSINOBIO (06185.HK) shares surged 5.01% in intraday trading, buoyed by the company's impressive third-quarter financial results and the strong performance of its core product. The biotechnology firm's stock has been on an upward trajectory, continuing its momentum from earlier in the week.

The company reported a remarkable 842.01% year-over-year increase in net profit attributable to shareholders, reaching RMB27.93 million for the third quarter. Revenue for the same period climbed 17.67% to RMB310 million, showcasing robust growth in its operations. This stellar performance has caught the attention of investors, driving the stock's significant intraday gain.

CANSINOBIO's success can be largely attributed to its flagship product, MenHibrix, the only quadrivalent meningococcal conjugate vaccine available in China's meningitis vaccine market. The innovative advantages of MenHibrix have led to increased market share, contributing significantly to the company's 22.13% revenue growth in the first nine months of the year. With the company swinging to a profit of RMB14.44 million for the first three quarters, compared to a loss in the same period last year, investors appear optimistic about CANSINOBIO's future prospects in the competitive biotech landscape.